Content Sponsored by Orasis
Peer-to-Peer Academy Sponsor
Orasis
Thank you to Orasis for sponsoring and supporting Peer-to-Peer Academy. Below, you will find all content related to the Orasis Qlosi corrective presbyopia eye drop.
About Orasis
Orasis Pharmaceuticals is an ophthalmic pharmaceutical company dedicated to reshaping vision possibilities for adults living with presbyopia. The company has developed Qlosi® (pilocarpine HCl ophthalmic solution) 0.4%, a corrective eye drop indicated for the treatment of presbyopia in adults—the gradual, age-related decline in near vision that affects nearly two billion people worldwide.
Qlosi works through pupil modulation, using a low-dose formulation of pilocarpine to create a pinhole effect that increases depth of field and improves near visual acuity. It is available by prescription in the U.S. and may be dosed once or twice daily per eye. Full prescribing information is available at qlosiecp.com/.
Orasis is led by a team of experienced pharmaceutical and eye care industry executives whose expertise spans clinical development, regulatory affairs, and commercial strategy. Backed by a group of leading life science and healthcare investors, the company is focused on delivering meaningful, accessible solutions for patients and the eye care professionals who treat them.
“In my practice, Qlosi's low-concentration formulation and favorable tolerability make it a safe, effective, and flexible option for patients wanting better near vision after cataract surgery.”
Sheri Rowen, MD, FACS
NVISION Eye Centers
